Benzodiazepines

• 

  Subject Areas on Research

  • A combined treatment approach to anxiety in the medically ill. 
  • A comparison of the efficacy of stimulus control for medicated and nonmedicated insomniacs. 
  • A phase 1 trial of SGN-CD70A in patients with CD70-positive, metastatic renal cell carcinoma. 
  • A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. 
  • A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. 
  • A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. 
  • A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). 
  • A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone. 
  • A selective imidazobenzodiazepine antagonist of ethanol in the rat. 
  • Adinazolam sustained-release treatment of panic disorder: a double-blind study. 
  • Adjunctive risperidone, olanzapine and quetiapine for the treatment of hospitalized patients with bipolar I disorder: a retrospective study. 
  • Adjunctive use of olanzapine in mood disorders: five case reports. 
  • Alprazolam for endogenous depression. 
  • Alprazolam reduces stress hyperglycemia in ob/ob mice. 
  • Alprazolam-induced manic reaction. 
  • Altered gabaa receptor subunit and splice variant expression in rats treated with chronic intermittent ethanol. 
  • Annals of Emergency Medicine Journal Club. Are 2 drugs better than 1 for acute agitation? A discussion on black box warnings, waiver of informed consent, and the ethics of enrolling impaired subjects in clinical trials: Answers to the January 2013 Journal Club questions. 
  • Antipsychotic drug effects on brain morphology in first-episode psychosis. 
  • Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. 
  • Association of Time to Treatment With Short-term Outcomes for Pediatric Patients With Refractory Convulsive Status Epilepticus. 
  • Associations between Benzodiazepine Use and Neuropsychological Test Scores in Older Adults. 
  • Atypical antipsychotic drugs and diabetes mellitus in a large outpatient population: a retrospective cohort study. 
  • Atypical antipsychotic drugs and hyperglycemia in adolescents. 
  • Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. 
  • Benzodiazepine and beta-adrenergic receptor ligands independently stimulate phospholipid methylation. 
  • Benzodiazepine anti-anxiety agents: prevalence and correlates of use in a southern community. 
  • Benzodiazepine use and cognitive function among community-dwelling elderly. 
  • Benzodiazepine use and risk of recurrence in bipolar disorder: a STEP-BD report. 
  • Benzodiazepine withdrawal delirium with catatonic features. Occurrence in patients with partial seizure disorders. 
  • Benzodiazepines protect hippocampal neurons from degeneration after transient cerebral ischemia: an ultrastructural study. 
  • Benzodiazepines, posttraumatic stress disorder, and veterans: good news and why we're not done yet. 
  • Bupropion treatment of olanzapine-associated weight gain: an open-label, prospective trial. 
  • Buspirone, chlordiazepoxide and diazepam effects in a zebrafish model of anxiety. 
  • COMT158 polymorphism and hostility. 
  • Case report: possible neuroleptic malignant syndrome associated with olanzapine. 
  • Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. 
  • Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. 
  • Cholecystokinin excites interneurons in rat basolateral amygdala. 
  • Chronic refractory dyspnoea--evidence based management. 
  • Clinical considerations in transitioning patients with epilepsy from clonazepam to clobazam: a case series. 
  • Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy? 
  • Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. 
  • Comment on Nasrallah et al: lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol. 
  • Comment: Addiction liability of benzodiazepines and buspirone. 
  • Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. 
  • Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. 
  • Comparison of the effects of diphenylbarbituric acid, phenobarbital, pentobarbital and secobarbital on GABA-mediated inhibition and benzodiazepine binding. 
  • Consensus statement on depression, anxiety, and functional gastrointestinal disorders. 
  • Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. 
  • Continuation treatment of panic disorder with high-potency benzodiazepines. 
  • Contributions of benzodiazepines to cancer therapy. 
  • Crystal structures of the anticancer clinical candidates R115777 (Tipifarnib) and BMS-214662 complexed with protein farnesyltransferase suggest a mechanism of FTI selectivity. 
  • Defining an appropriate management strategy for social anxiety disorder. 
  • Design of the blockade of the glycoprotein IIb/IIIa receptor to avoid vascular occlusion (BRAVO) trial. 
  • Determinants of seizure threshold in ECT: benzodiazepine use, anesthetic dosage, and other factors. 
  • Development of new pharmacological agents for epilepsy: lessons from the kindling model. 
  • Do benzodiazepines have a role in the prevention or treatment of coronary heart disease and other major medical disorders? 
  • Does olanzapine have any antidepressant effect? 
  • Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial. 
  • Dopamine D2 receptor occupancy and cognition in schizophrenia: analysis of the CATIE data. 
  • Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. 
  • Dosing recommendations and prescribing patterns for depressed medically ill hospitalized older patients. 
  • Dr. Capehart replies. 
  • Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. 
  • Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. 
  • Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. 
  • Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. 
  • Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. 
  • Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. 
  • Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. 
  • Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia. 
  • Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. 
  • Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. 
  • Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial. 
  • Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. 
  • Efficacy of olanzapine and risperidone in schizophrenia: a randomized double-blind crossover design. 
  • Efficacy of olanzapine in social anxiety disorder: a pilot study. 
  • Establishing the neurobiologic basis of treatment in children and adolescents with generalized anxiety disorder. 
  • Estimating suicidality as an outcome measure in clinical trials of suicide in schizophrenia. 
  • Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease. 
  • Evaluating short- and long-term impacts of a Medicaid "lock-in" program on opioid and benzodiazepine prescriptions dispensed to beneficiaries. 
  • Evidence-based intervention for chronic refractory breathlessness: practical therapies that make a difference. 
  • Factors associated with treatment delays in pediatric refractory convulsive status epilepticus. 
  • Gabapentin Use in the Neonatal Intensive Care Unit. 
  • Gaps and opportunities in refractory status epilepticus research in children: a multi-center approach by the Pediatric Status Epilepticus Research Group (pSERG). 
  • Guidelines for endoscopy in pregnant and lactating women. 
  • Guidelines for sedation and anesthesia in GI endoscopy. 
  • High-frequency organization and synchrony of activity in the purkinje cell layer of the cerebellum. 
  • Impact of a palliative care program on end-of-life care in a neonatal intensive care unit. 
  • Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1. 
  • Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. 
  • Impact of restarting home neuropsychiatric medications on sedation outcomes in medical intensive care unit patients. 
  • Impact of symptoms of generalized anxiety disorder on the course of late-life depression. 
  • Implications of atypical antipsychotic prescribing in the intensive care unit. 
  • Indiplon is a high-affinity positive allosteric modulator with selectivity for alpha1 subunit-containing GABAA receptors. 
  • Insight in first-episode psychosis. 
  • International advances in the treatment of social phobia. 
  • Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. 
  • Long-term neuroprotection by benzodiazepine full versus partial agonists after transient cerebral ischemia in the gerbil [corrected]. 
  • Low-dose opioids should be considered for symptom relief also in advanced chronic obstructive pulmonary disease (COPD). 
  • Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council on Clinical Cardiology. 
  • Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled. 
  • Mitochondrial benzodiazepine receptors regulate steroid biosynthesis. 
  • Motor cortex excitability after vagus nerve stimulation in major depression. 
  • NMR studies of an immunomodulatory benzodiazepine binding to its molecular target on the mitochondrial F(1)F(0)-ATPase. 
  • Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. 
  • Neuropsychological course in the prodrome and first episode of psychosis: findings from the PRIME North America Double Blind Treatment Study. 
  • New Developments in Insomnia Medications of Relevance to Mental Health Disorders. 
  • Olanzapine and clozapine increase the GABAergic neuroactive steroid allopregnanolone in rodents. 
  • Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions. 
  • Olanzapine and haloperidol in first episode psychosis: two-year data. 
  • Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. 
  • Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. 
  • Olanzapine increases allopregnanolone in the rat cerebral cortex. 
  • Olanzapine interactions with nicotine and mecamylamine in rats: effects on memory function. 
  • Olanzapine on trial. 
  • Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose. 
  • Olanzapine-associated diabetes mellitus. 
  • Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature. 
  • One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. 
  • Panic disorder and social phobia: current treatments and new strategies. 
  • Panic disorder: making clinical sense of the latest research. 
  • Paroxetine in the treatment of generalised anxiety disorder. 
  • Patterns of Sedation Weaning in Critically Ill Children Recovering From Acute Respiratory Failure. 
  • Pharmacological management of dyspnoea. 
  • Pharmacotherapy in stroke rehabilitation. 
  • Pharmacotherapy of generalized anxiety disorder. 
  • Pharmacotherapy of social anxiety disorder. 
  • Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings. 
  • Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. 
  • Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. 
  • Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. 
  • Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. 
  • Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol. 
  • Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. 
  • Psychopharmacologic treatment of children and adolescents with anxiety disorders. 
  • Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. 
  • Radiation inactivation studies of the benzodiazepine/gamma-aminobutyric acid/chloride ionophore receptor complex. 
  • Randomized Trial of the Effect of Four Second-Generation Antipsychotics and One First-Generation Antipsychotic on Cigarette Smoking, Alcohol, and Drug Use in Chronic Schizophrenia. 
  • Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. 
  • Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. 
  • Regulatory perspectives and the benzodiazepines. 
  • Relationship between antidepressant and anxiolytic/hypnotic prescribing: a mixed-methods study. 
  • Relationship of past depressive episodes to symptom severity and treatment response in panic disorder with agoraphobia. 
  • Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy. 
  • Relaxation to assist sleep medication withdrawal. 
  • Repeated seizures induce long-term increase in hippocampal benzodiazepine receptors. 
  • Restricting Benzodiazepines to Short-Term Prescription. 
  • Results of phase 3 of the CATIE schizophrenia trial. 
  • Revisiting cycloid psychosis: a case of an acute, transient and recurring psychotic disorder. 
  • Safety and Efficacy of Remimazolam Compared With Placebo and Midazolam for Moderate Sedation During Bronchoscopy. 
  • Safety and antipsychotic efficacy of "forced" intramuscular olanzapine over five days: a case report. 
  • Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study. 
  • Sedation of children for emergency imaging. 
  • Severe withdrawal symptoms after discontinuation of alprazolam in eight patients with combat-induced posttraumatic stress disorder. 
  • Social phobia: biological aspects and pharmacotherapy. 
  • Social phobia: issues in assessment and management. 
  • Spousal depression, anxiety, and suicide after myocardial infarction. 
  • Stimulation of cholecystokinin-A receptors with Gl181771X: a failed clinical trial that did not test the pharmacogenetic hypothesis for reduction of food intake. 
  • Stiripentol in Dravet syndrome: results of a retrospective U.S. study. 
  • The association of anticonvulsant use with fractures in spinal cord injury. 
  • The association of psychotropic medication use with the cognitive, functional, and neuropsychiatric trajectory of Alzheimer's disease. 
  • The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials. 
  • The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. 
  • The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. 
  • The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients. 
  • The pharmacologic management of insomnia in patients with HIV. 
  • The role of benzodiazepines in breathlessness: a single site, open label pilot of sustained release morphine together with clonazepam. 
  • Time from convulsive status epilepticus onset to anticonvulsant administration in children. 
  • Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. 
  • Time-lapse mapping of cortical changes in schizophrenia with different treatments. 
  • Treating delirium among elderly patients. 
  • Treatment of social phobia with benzodiazepines. 
  • Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. 
  • Understanding the sleep-wake cycle: sleep, insomnia, and the orexin system. 
  • Use of antidepressants by nonpsychiatrists in the treatment of medically ill hospitalized depressed elderly patients. 
  • Use of benzodiazepines as anxiolytics in neonates: are we there yet? 
  • Use of benzodiazepines in panic disorder. 
  • What CATIE found: results from the schizophrenia trial. 
  • Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats. 
  • [3H]-flunitrazepam-labeled benzodiazepine binding sites in the hippocampal formation in autism: a multiple concentration autoradiographic study. 
  • [Benzodiazepine receptors of the mouse glioblastoma cell line: the anomalous effect of gamma-aminobutyric acid on diazepam binding]. 
  • [Benzodiazepines consumption and risk of dependence in institutionalized geriatric patients]. 
  • [Molecular mechanisms of the pharmacologic action of benzodiazepines]. 
  • gamma-Aminobutyric acid(A) neurotransmission and cerebral ischemia. 
• 

  Keywords of People

  • Schwartz-Bloom, Rochelle D., Professor Emeritus of Pharmacology & Cancer Biology, Duke Science & Society